Avastin meets goal in first Phase III trial in ovarian cancer
This article was originally published in Scrip
Executive Summary
The first Phase III trial of Roche's Avastin (bevacizumab) in previously untreated advanced ovarian cancer has shown that the anti-angiogenic monoclonal antibody drug has improved progression-free survival (PFS) when used for a longer duration, but not a shorter duration of therapy.